Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Tau biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Context Early detection of prodromal Alzheimer disease (AD) is important because new disease-modifying therapies are most likely to be effective when initiated during the early stages of disease. Objectives To assess the ability of the cerebrospinal fluid (CSF) biomarkers total tau (T-tau), phosphorylated tau (P-tau), and β-amyloid 1-42 (Aβ42) to predict future development of AD dementia within 9.2 years in patients with mild cognitive impairment (MCI) and to compare CSF biomarkers between early and late converters to AD. Design A clinical study with a median follow-up of 9.2 years (range, 4.1-11.8 years).

What this study adds

Evidence grade: Low

The record lists 137 participants. This study took spinal-fluid samples from 137 people who already had mild cognitive impairment and followed them for a median of 9.2 years (range 4.1–11.8) to see who developed Alzheimer dementia. Reported effect size: 53.7%; 15.7%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Buchhave, P., Minthon, L., Zetterberg, H., Wallin, A. K., Blennow, K., & Hansson, O. (2012). Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Archives of general psychiatry. https://doi.org/10.1001/archgenpsychiatry.2011.155

Vancouver

Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Archives of general psychiatry. 2012. doi:10.1001/archgenpsychiatry.2011.155. PMID: 22213792.

BibTeX

@article{buchhave2012-22213792,
  author  = {Buchhave, P. and Minthon, L. and Zetterberg, H. and Wallin, A. K. and Blennow, K. and Hansson, O.},
  title   = {{Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia}},
  journal = {Archives of general psychiatry},
  year    = {2012},
  doi     = {10.1001/archgenpsychiatry.2011.155},
  pmid    = {22213792},
  url     = {https://doi.org/10.1001/archgenpsychiatry.2011.155}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This study took spinal-fluid samples from 137 people who already had mild cognitive impairment and followed them for a median of 9.2 years (range 4.1–11.8) to see who developed Alzheimer dementia. Its title reports that one amyloid marker (β-amyloid 1-42) was already fully changed 5 to 10 years before dementia began, while tau markers were not. The summary held here ends before the results, so no accuracy figures are available, and as an observational study it cannot show that amyloid causes dementia or that any treatment would prevent it.

Study details

How this study scored 56/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 4 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 2 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 6 of 7; Citations per year 4 of 5; Impact for its field and year 6 of 6; Cited by studies here 4 of 6; Still being cited 3 of 4; Senior author's track record 1 of 4; Institution's track record 0 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 56 of 100.56 of 100 points earned44 not earned

Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Archives of general psychiatry)
Journal's citation record 4 / 4 Archives of General Psychiatry: journal h-index 543 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2012 — within 20 year(s) of the newest study here
Sample size 2 / 4 137 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 6 / 7 Cited 664 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 41.5 citations a year over 16 year(s) since 2012
Impact for its field and year 6 / 6 Cited 49.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 4 / 6 Cited by 50 other studies in this library
Still being cited 3 / 4 Cited 98 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author Peder Buchhave: h-index 12 (OpenAlex, whole career)
Institution's track record 0 / 3 Skåne University Hospital: institution h-index 625 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 22213792)
Free to read 0 / 2 Behind a paywall — scores zero
Total 56 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 24.

Later studies that cite this one

50 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Tau biomarkers from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Tau biomarkers

See all studies in Tau biomarkers →